Cancundude...I get it. Frustrating we didn't hit. But the positive side is we now have new evidence in the potential utility of apabetalone. The time honored generation of data to support the hypothesis is paramount. If not, it would be equivalent to snake oil. Just has to be that way...no way around this. Will there be a "fast track" offer by the FDA to expidited commercialization? Not without contingencies I fear.

I agree we need a partnership, buyout or some other agreement with a firm to realistically advance this prospect. 

I will also add that DM and the RVX team are to be complemented to be able to stay afloat over the last 20 years in the face of repeated dissapointments and relentless fundraising. To me this is simply amazing for a biotech that basically has a "one trick pony", from Canada and not listed on a major exchange in the states.